Cancer Supportive Care Drug Market

Global Cancer Supportive Care Drugs Market is valued at USD 20.57 Billion in 2021 and is expected to reach USD 23.79 Billion by 2028 with a CAGR of 2.1% over the forecast period.

Global Cancer Supportive Care Drugs Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2022-2028- Increasing prevalence of cancer patients, rising initiatives taken by the government to achieve universal access to psychosocial care of cancer patients and growing research and development activities in are some of the major factors anticipated to drive the growth of Global Cancer Supportive Care Drugs Market.

Scope of Global Cancer Supportive Care Drugs Market Report–

Cancer supportive care drugs are used to ease the harmful side effects of cancer treatment by protecting body cells or organs. The symptoms of disease treatments are can be calmed by cancer supportive care otherwise called soothing. Many instances of disease halted because of genuine complications like low platelet counts. Cancer supportive drugs like CSFs permit patients to proceed with cancer therapies on top of in different cases; it additionally permits higher portions of cancer treatments. There is rising focus on cancer as it is the main causes of death around the world. The side effects of cancer therapies are fertility problem, hair loss, pain, fatigue, depression, heartburn, indigestion, sexual issues, bone illnesses and other secondary effects. Some of these side effects are an extremely severe medical condition that requires to be treated and others are difficult or upsetting but are not damaging to health.

The Covid-19 pandemic has shown negative impact on the global cancer supportive drugs market. During Covid-19 pandemic, increasing focus of medical sector shifted only on treating the Covid patients. Due to lockdown and social distancing blood supply shortages and cancellation of blood drives, and infection among donors which hampered the market growth. Also, people who are being treated for cancer may be at increased risk of severe Covid-19. Clinical outcomes of Covid-19 are generally worse in people with cancer than in people without cancer immuno suppression and susceptibility to SARS-CoV-2 infection.

Global Cancer Supportive Care Drugs Market Segmentation:-

The global cancer supportive care drugs market is segmented based on type, distribution channel, application and region & country level. Based upon type, the global cancer supportive care drugs market is segmented into granulocyte-colony stimulating factors (G-CSF), erythropoietin-stimulating agents (ESA), antiemetics, Bisphosphonates, Opioids, non-steroidal anti-inflammatory drugs (NSAID) and others. Based upon distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies and online providers. On the basis of application, the market is segmented into breast cancer, lung cancer, melanoma, prostate cancer and others.

By Type:

• Granulocyte-Colony Stimulating Factors (G-CSF)
• Erythropoietin-Stimulating Agents (ESA)
• Antiemetic’s
• Bisphosphonates
• Opioids
• Non-Steroidal Anti-Inflammatory Drugs (NSAID)
• Others

By Distribution Channel:

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Providers

By Application:

• Breast Cancer
• Lung Cancer
• Melanoma
• Prostate Cancer
• Other Cancers

Key Players of Global Cancer Supportive Care Drugs Market-

Some of the key players for global cancer supportive care drugs market are

• Johnson & Johnson
• Novartis Ag.
• Hoffmann LA- Roche Ltd
• Baxter International Inc
• Fagron Group BV
• Kyowa Hakko Kirin Co Ltd.
• Acacia Pharma Ltd.
• Amgen Inc
• APR Applied Pharma Science Research S.A.
• Teva Pharmaceuticals Industries Ltd
• others.

Recent Developments

News: FDA Approved Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA (PEGFILGRASTIM-APGF)

On June 11^th, 2020; Pfizer Inc announced the United States (U.S.) Food and Drug Administration (FDA) had approved NYVEPRIA a biosimilar to Neulasta. NYVEPRIA is demonstrated to diminish the rate of disease, as appeared by febrile neutropenia, in patients with non-myeloid malignancies getting myelosuppressive anti-cancer drugs related with a clinically critical rate of febrile neutropenia. The FDA endorsement of NYVEPRIA was a positive advance that would both empower cost savings and increment is able to admittance to a significant therapy choice. Chemotherapy-initiated febrile neutropenia is a moderately normal and extreme side effect of a few disease medicines that could cause significant inconveniences and can brought about the adjustment of treatment regimens. The FDA approval of NYVEPRIA furnished clinicians with an extra long-acting treatment choice that can helped with avoid contaminations in patients going through myelosuppressive chemotherapy.

Increasing Prevalence of Cancer Patients, Rising Number of Research and Development Activities in Biopharmaceutical Industry and Growing Number of Initiatives Taken by Government to Achieve Universal Access to Psychosocial Care of Cancer Patients are Driving the Market Growth

One of the major factors driving the growth of the global cancer supportive care drugs market is increased prevalence of cancer patients. Growing number of cases of cancer has led to an increase in the number of patients going for cancer therapies. As cancer treatments have side effects and cancer supportive care drugs are used to ease the side effects of cancer therapy. Hence, rising cancer patients increases the growth of cancer supportive care drugs market. For example; according to the World Health Organization (WHO), there are 18.1 million new cancer cases and 9.6 million deaths were recorded in 2018.

In addition, another factor supplementing the growth of global cancer supportive care drugs market is rising number of initiatives taken by government to achieve universal access to psychosocial care of cancer patients. The increasing supportive care has also exponentially grown because of the dramatic shift in public expectations towards cancer care providers in all parts of the world. Therefore, the doctor’s focus on mental health of cancer patients, thus families shared decision making, and attention to the personhood of patients, to the relief of their suffering, and to their psychological and physical wellbeing throughout the course of their disease. Cancer care centers and other centers of medical care in most regions have been inadequately equipped to address these demands and to make person-centered care and shared decision making a reality  these initiatives by government to support mental health of cancer patients further adding growth of market. Also, rising research and development activities in the biopharmaceutical industry is also augmenting the market growth. For instance; as per the news published on October 25^th, 2021, Novartis top-line results for CANOPY-1 Phase III review support further assessment of canakinumab in lung cancer. Moreover, rising disposable income and improved healthcare structure is another factor fostering the market growth.

However, high cost of medication and side effects associated with cancer supportive care drugs may restrain the growth of the cancer supportive care ug market. In spite of that, research and development activities and emerging markets will provide beneficial opportunities for the further growth of the global cancer supportive care drugs market.

North America is Expected to Dominate the Global Cancer Supportive Care Drugs Market

North America is expected to dominate the global cancer supportive care drugs market due to the increasing prevalence of cancer in this region and high research and development in this field. For example; according to the Centers for Disease Control and Prevention (CDC), in 2019, there are about 220,400 patients diagnosed with cancer, in Canada. These growing number of cancer patients are boosting the market growth. In addition, this region have highly developed healthcare infrastructures. Apart from that, high investment or R & D for oncology is also fostering the market growth in this region. For instance; as per the news published on June 11^th, 2021, Pfizer Inc announced that U.S. Food and Drug Administration (FDA) had approved NYVEPRIA a biosimilar to Neulasta.

Asia Pacific is expected to show a fastest growth in the global cancer supportive care drugs market due to growing number of cancer patients, rising awareness regarding cancer supportive care drugs and increasing investments on health and infrastructure supportive care drug market in the emerging economies like India and China. For instance; according to the National Central Cancer Registry of China, the number of cancer patients in China is about 2,865,174. Increasing number of cancer patients increase the market of the global cancer supportive care.

On Special Requirement Cancer Supportive Care drugs Market Report is also available for below region:

North America

• U.S.
• Canada

Europe

• Germany
• France
• U.K.
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Switzerland
• Belgium
• Rest of Europe

Asia-Pacific

• South Korea
• Japan
• China
• India
• Australia
• Philippines
• Singapore
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Colombia
• Brazil
• Argentina
• Peru
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Key Benefits of Global Cancer Supportive Care Drug Market Report-

• Global Cancer Supportive Care Drug Market report covers in-depth historical and forecasts analysis.
• Global Cancer Supportive Care Drug Market research report provides detailed information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, and Regional and Country levels.
• Global Cancer Supportive Care Drug Market report helps to identify opportunities in the marketplace.
• Global Cancer Supportive Care Drug Market report covers extensive analysis of emerging trends and the competitive landscape.

 Trending Reports:

Cancer Vaccines Market 2021-2027

Cancer Biomarkers Market 2021-2027

Cancer Biological Therapy Market 2021-2027

Cancer Stem Cells Market 2021-2027

Frequently Asked Questions (FAQ) :